Loading...
Loading...
Browse all stories on DeepNewz
VisitPublication of HRO761 Initial Clinical Trial Results by Mid-2025
Yes • 50%
No • 50%
Publication records from major scientific journals like Nature, Science, or NEJM
Breakthrough WRN Inhibitor HRO761 Targets MSI Cancers, Poised for Clinical Trials
Apr 24, 2024, 07:56 PM
Recent research has led to the discovery of a novel inhibitor, HRO761, targeting Werner Helicase (WRN), which shows synthetic lethality in microsatellite instability (MSI) cancers. This breakthrough, published in Nature, was achieved through chemoproteomic techniques that identified a covalent allosteric inhibitor of WRN. The research, spearheaded by NIBR and involving Vividion, marks a significant advancement in cancer treatment, particularly by transforming an ATP-competitive compound into an ATP-cooperative analogue. The development is poised for clinical testing to evaluate its effectiveness in human models of disease.
View original story
Yes • 50%
No • 50%
Positive results • 33%
Neutral results • 34%
Negative results • 33%